

How to pay for national pharmacare

November 26 2018

A new analysis in *CMAJ* (*Canadian Medical Association Journal*) www.cmaj.ca/lookup/doi/10.1503/cmaj.180897 outlines the potential government cost of a national Canadian pharmacare program and sets out approaches to shifting the funding for drugs in Canada to realize billions in savings.

"We believe there is a compelling argument for the <u>federal government</u> to raise the incremental revenues needed to implement this long-recommended expansion of Canadian medicare," write Drs. Michael Wolfson, Faculties of Medicine and Law, University of Ottawa, and Steven Morgan, School of Population and Public Health, University of British Columbia.

Implementing a national pharmacare program in 2020 would require \$9.7 billion in public funding and result in \$13.5 billion in savings to the private sector because of lower costs of private insurance, according to estimates from the Parliamentary Budget Officer.

The authors suggest using a mix of federal revenue sources, including relatively small increases in personal income taxes (0.5 percentage points), corporate tax rates (1 percentage point) and GST (0.25 percentage points).

For policy-makers, advanced modelling tools can help inform the different approaches to funding a national pharmacare program.

"Without national pharmacare by 2020, Canadians could be paying \$4.2



billion more for medicines than they would need to under a universal, comprehensive public pharmacare plan," the authors write. "The question, therefore, isn't whether Canada can afford national pharmacare; rather, it is how government should raise the needed public revenues and, correspondingly, who should benefit from the billions of dollars in net savings as a result."

More information: Canadian Medical Association Journal (2018). www.cmaj.ca/lookup/doi/10.1503/cmaj.180897

Provided by Canadian Medical Association Journal

Citation: How to pay for national pharmacare (2018, November 26) retrieved 6 May 2024 from https://medicalxpress.com/news/2018-11-national-pharmacare.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.